Latest news with #JournalofCardiacFailure
Time of India
06-05-2025
- Health
- Time of India
Most Indian heart failure patients not getting lifesaving therapy, finds survey
Nagpur: A first-of-its-kind nationwide physician survey found that a majority of heart failure (HF) patients in India are not receiving guideline-directed medical therapy (GDMT) — a proven set of treatments that can significantly reduce hospitalisation and means using the best combination of medicines that have been proven to work for heart failure. These medicines help the heart pump better, reduce symptoms like breathlessness or swelling, and most importantly, help patients live longer and stay out of the across 27 states and one Union territory, the study gathered responses from over 5,000 doctors, making it one of the most comprehensive real-world assessments of heart failure care in India to date. The study, which recently appeared in the Journal of Cardiac Failure, was spearheaded by Dr Shantanu Sengupta, a senior cardiologist and researcher from Sengupta, the lead author, warned that the findings expose a serious gap in the standard of care for common Indian patients suffering from heart failure."This data tells us that many patients who should be receiving GDMT are simply not getting it — either due to lack of physician awareness, patient affordability, or systemic barriers," said Dr Sengupta, speaking to 54% of doctors said that only 1 in 4 of their patients were on proper GDMT, just 15% believed that more than three-quarters of their patients were receiving the recommended care. This means that thousands of patients may be left vulnerable to worsening heart failure due to under-treatment, despite clinical guidelines established by global and Indian cardiology typically includes a combination of medications, each targeting different aspects of heart failure pathology. When used in appropriate doses and combinations, GDMT has been shown to reduce mortality by nearly 60% in certain groups of heart failure patients."Patients and families must ask whether the following treatment plan includes GDMT. It's a matter of life and death," Dr Sengupta Common Patients Should Do* Know your EF (Ejection Fraction): Ask your doctor about your EF status* Demand clarity on medicines: Check if you're receiving beta-blockers, RAAS inhibitors* Monitor symptoms: Shortness of breath, leg swelling, and fatigue* Regular follow-up: GDMT needs regular dose adjustments and monitoringGDMT Gap in India* 5,012 doctors surveyed across 27 states and 1 UT* 53% physicians, 44% cardiologists, 2% endocrinologists* 54% said only 1 in 4 patients receive GDMT* 15% said more than 75% receive GDMT* 58% doctors in South zone say 25% patients on GDMT
Yahoo
12-02-2025
- Health
- Yahoo
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fraction MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study demonstrated large and statistically significant reductions in hospital visits (hospitalizations and emergency department visits) and length of stay after Barostim implantation, compared to before. The research was published simultaneously and is available now in the Journal of Cardiac Failure. 'Despite contemporary medications, the clinical and economic burden of heart failure remains unacceptably high. This new study showing significant reductions in real-world healthcare utilization associated with the Barostim implant is critically important for clinicians and payers when considering this device for their patients,' said Jacob Abraham, MD, Section Head of Advanced Heart Failure at Providence Heart Institute in Portland, Ore. 'While we know Barostim plus medications demonstrates long-term improvements in symptoms and quality of life, we now have compelling real-world evidence supporting a significant reduction in healthcare utilization as well.' This analysis was performed using data from the Premier Healthcare Database, a large all-payer database including data from more than 1,300 institutions. Three hundred and six (306) Barostim patients were identified in the data set. Comparisons were performed for the 12 months prior to Barostim implant and for an average of almost two years post-implant (1.92±1.87 years). Length of stay was found to be significantly reduced. Hospital visits (hospitalizations and emergency department visits) were categorized as all-cause, cardiovascular, and heart failure related. The analysis found: 86% reduction in all-cause hospital visits (p<0.0001) 84% reduction in cardiovascular hospital visits (p<0.0001) 85% reduction in heart-failure hospital visits (p<0.0001) 'Congratulations to Dr. Jacob Abraham and co-authors for this important real-world analysis demonstrating remarkable reductions in healthcare utilization with Barostim,' said Dr. Philip Adamson, Chief Medical Officer of CVRx. 'We believe this study adds to the growing and consistent body of evidence supporting the clinical utility of Barostim. This is another example of our commitment to further develop and disseminate a strong pipeline of clinical and economic data supporting the many benefits of this therapy.' About CVRx, is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Media Contact:Emily Meyers651.338.6204emeyers@ Investor Contact:Mark Klausner or Mike VallieICR Healthcare443.213.0501ir@ in to access your portfolio
